These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19728346)

  • 21. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states.
    Ochoa-Sanchez R; Comai S; Spadoni G; Bedini A; Tarzia G; Gobbi G
    Neurosci Lett; 2014 Feb; 561():156-61. PubMed ID: 24406151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT(1) and MT(2) melatonin receptors.
    Spadoni G; Bedini A; Orlando P; Lucarini S; Tarzia G; Mor M; Rivara S; Lucini V; Pannacci M; Scaglione F
    Bioorg Med Chem; 2011 Aug; 19(16):4910-6. PubMed ID: 21775151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
    Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.
    Ettaoussi M; Sabaouni A; Pérès B; Landagaray E; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
    ChemMedChem; 2013 Nov; 8(11):1830-45. PubMed ID: 24031039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological activity of new melatonin dimeric derivatives.
    Di Giacomo B; Bedini A; Spadoni G; Tarzia G; Fraschini F; Pannacci M; Lucini V
    Bioorg Med Chem; 2007 Jul; 15(13):4643-50. PubMed ID: 17481904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands.
    Hu Y; Ho MK; Chan KH; New DC; Wong YH
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2582-5. PubMed ID: 20227878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat.
    Fisher SP; Davidson K; Kulla A; Sugden D
    J Pineal Res; 2008 Sep; 45(2):125-32. PubMed ID: 18298466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and melatoninergic potency of new N-acyl 8,9-dihydro-4-methoxy-7H-2-benzo[de]quinolinalkanamines.
    Tsotinis A; Eleutheriades A; Hough KA; Davidson K; Sugden D
    Bioorg Chem; 2007 Apr; 35(2):189-204. PubMed ID: 17223160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and pharmacological evaluation of pentacyclic 6a,7-dihydrodiindole and 2,3-dihydrodiindole derivatives as novel melatoninergic ligands.
    Attia MI; Witt-Enderby PA; Julius J
    Bioorg Med Chem; 2008 Aug; 16(16):7654-61. PubMed ID: 18657980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.
    Durieux S; Chanu A; Bochu C; Audinot V; Coumailleau S; Boutin JA; Delagrange P; Caignard DH; Bennejean C; Renard P; Lesieur D; Berthelot P; Yous S
    Bioorg Med Chem; 2009 Apr; 17(8):2963-74. PubMed ID: 19329323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.
    Mésangeau C; Fraise M; Delagrange P; Caignard DH; Boutin JA; Berthelot P; Yous S
    Eur J Med Chem; 2011 May; 46(5):1835-40. PubMed ID: 21392858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, NMR conformational analysis and pharmacological evaluation of 7,7a,13,14-tetrahydro-6H-cyclobuta[b]pyrimido[1,2-a:3,4-a']diindole analogues as melatonin receptor ligands.
    Attia MI; Güclü D; Hertlein B; Julius J; Witt-Enderby PA; Zlotos DP
    Org Biomol Chem; 2007 Jul; 5(13):2129-37. PubMed ID: 17581657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
    Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
    J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.
    Mor M; Rivara S; Pala D; Bedini A; Spadoni G; Tarzia G
    Expert Opin Ther Pat; 2010 Aug; 20(8):1059-77. PubMed ID: 20533893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-throughput screening assay for new ligands at human melatonin receptors.
    Yan JH; Su HR; Boutin JA; Renard MP; Wang MW
    Acta Pharmacol Sin; 2008 Dec; 29(12):1515-21. PubMed ID: 19026172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 7-Substituted-melatonin and 7-substituted-1-methylmelatonin analogues: effect of substituents on potency and binding affinity.
    Faust R; Garratt PJ; Trujillo Pérez MA; Piccio VJ; Madsen C; Stenstrøm A; Frølund B; Davidson K; Teh MT; Sugden D
    Bioorg Med Chem; 2007 Jul; 15(13):4543-51. PubMed ID: 17459711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation.
    Elsner J; Boeckler F; Davidson K; Sugden D; Gmeiner P
    Bioorg Med Chem; 2006 Mar; 14(6):1949-58. PubMed ID: 16290939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
    Rivara S; Mor M; Silva C; Zuliani V; Vacondio F; Spadoni G; Bedini A; Tarzia G; Lucini V; Pannacci M; Fraschini F; Plazzi PV
    J Med Chem; 2003 Apr; 46(8):1429-39. PubMed ID: 12672242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers.
    Ayoub MA; Levoye A; Delagrange P; Jockers R
    Mol Pharmacol; 2004 Aug; 66(2):312-21. PubMed ID: 15266022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.